AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37598196 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise consisting of high-intensity interval training on a stationary exercise bike and machine-based progressive resistance training offered three times a week for 24 weeks during NACT
Number of subjects: 120
Study 37598196 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 37598196 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 120
Study 37598236 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-sensitive restriction enzyme digestion followed by sequencing (MRE-Seq) using cfDNA with SacII enzyme digestion.
Number of subjects: 191
Study 37598236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer signal origin (CSO) model using deep neural network (DNN) analysis.
Number of subjects: 191
Study 37598327 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS directed to the prefrontal cortex for 30 minutes
Number of subjects: 41
Study 37598327 — intervention group
Group type: COMPARATOR
Intervention: Baseline performance
Number of subjects: 41
Study 37598358 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP) for frail patients (n=79)
Number of subjects: 2212
Study 37598358 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive distal pancreatectomy (MIDP) for nonfrail patients (n=2133)
Number of subjects: 2212
Study 37598358 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP) for patients with mFI ≥0.27
Number of subjects: 2212
Study 37598389 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial micro-incentive (R50 [$3] food voucher) for rapid HIV testing
Number of subjects: 15675
Study 37598389 — intervention group
Group type: COMPARATOR
Intervention: Testing only (control arm)
Number of subjects: 15675
Study 37598625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 226
Study 37598625 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga
Number of subjects: 226
Study 37598625 — intervention group
Group type: COMPARATOR
Intervention: Stress Education (Control)
Number of subjects: 226
Study 37598656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg once daily
Number of subjects: 453
Study 37598656 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg once daily (4 weeks on/2 weeks off)
Number of subjects: 453
Study 37598747 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D optical imaging (3DO)
Number of subjects: 95
Study 37598748 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Renal Diet (NNRD)
Number of subjects: 60
Study 37598748 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 60
Study 37598750 — intervention group
Group type: EXPERIMENTAL
Intervention: 15g whey protein (ERW15, n = 10)
Number of subjects: 40
Study 37598750 — intervention group
Group type: EXPERIMENTAL
Intervention: 35g whey protein (ERW35, n = 10)
Number of subjects: 40
Study 37598750 — intervention group
Group type: EXPERIMENTAL
Intervention: 60g whey protein (ERW60, n = 10)
Number of subjects: 40
Study 37598750 — intervention group
Group type: COMPARATOR
Intervention: 35g whey protein after energy balanced diet (EBW35, n = 10)
Number of subjects: 40
Study 37598795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose as treatment for heart failure with iron deficiency
Number of subjects: 3065
Study 37598795 — intervention group
Group type: COMPARATOR
Intervention: HFrEF therapy including beta-blocker
Number of subjects: 3065
Study 37598795 — intervention group
Group type: COMPARATOR
Intervention: HFrEF therapy including ARNI
Number of subjects: 3065
Study 37598795 — intervention group
Group type: COMPARATOR
Intervention: HFrEF therapy including MRA
Number of subjects: 3065
Study 37598862 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 54
Study 37598863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional myotomy (CM)
Number of subjects: 115
Study 37598863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique fiber-sparing myotomy (OFS)
Number of subjects: 115
Study 37599360 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training combined with cognitive training
Number of subjects: 62
Study 37599360 — intervention group
Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 62
Study 37599908 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib 2.5 mg QD (daily dosing group)
Number of subjects: 161
Study 37599908 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib 20 mg QD for 8 weeks, then either 20 mg once-weekly or 2.5 mg QD
Number of subjects: 161
Study 37600483 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 336
Study 37600483 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy
Number of subjects: 336
Study 37600550 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin aglycone 250 mg
Number of subjects: 10
Study 37600550 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin aglycone 500 mg
Number of subjects: 10
Study 37600550 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin aglycone 1000 mg
Number of subjects: 10
Study 37600800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10 dose of Sputnik V vaccine
Number of subjects: 0
Study 37600800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/5 dose of Sputnik V vaccine
Number of subjects: 0
Study 37600829 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocetra™-OTS (apoptotic cells)
Number of subjects: 21
Study 37600852 — intervention group
Group type: EXPERIMENTAL
Intervention: BIO-initiated
Number of subjects: 2927
Study 37600852 — intervention group
Group type: COMPARATOR
Intervention: BIO-non-initiated
Number of subjects: 2927
Study 37600866 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal bridging
Number of subjects: 112
Study 37600866 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure
Number of subjects: 112
Study 37600876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp (HNC) initiated by infusing insulin at 2 mU/kg/min and administering dextrose to maintain normoglycemia (4.0-6.0 mmol/L).
Number of subjects: 34
Study 37600876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp (HNC)
Number of subjects: 34
Study 37600936 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI + 5-FU/LV
Number of subjects: 56
Study 37600959 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE syndrome test
Number of subjects: 84
Study 37600959 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal naming test (ANT)
Number of subjects: 84
Study 37600959 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical flicker frequency (CFF)
Number of subjects: 84
Study 37600959 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three tests (PSE, ANT, CFF)
Number of subjects: 84
Study 37601010 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (1 to 10 μg/kg for 9 weeks)
Number of subjects: 202
Study 37601010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 37601238 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-path adrenal venous sampling (SP)
Number of subjects: 200
Study 37601238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipath adrenal venous sampling (MP)
Number of subjects: 200
Study 37601688 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized ctDNA monitoring assay utilizing tissue-based FoundationOne
Number of subjects: 396
Study 37601688 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 396
Study 37601688 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 396
Study 37601786 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI monitor-based nociception control
Number of subjects: 72
Study 37601786 — intervention group
Group type: COMPARATOR
Intervention: Conventional nociception control (remifentanil based on blood pressure and heart rate)
Number of subjects: 72
Study 37601885 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruplet therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone) followed by autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 0
Study 37601885 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-AHCT consolidation
Number of subjects: 0
Study 37601885 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance (MRD-SURE) after achieving MRD negativity
Number of subjects: 0
Study 37602251 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex locomotion
Number of subjects: 0
Study 37602251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath concept
Number of subjects: 0
Study 37602251 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37602376 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI using zotarolimus drug-eluting stents
Number of subjects: 1500
Study 37602376 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1500
Study 37602376 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1500
Study 37602418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical repellents
Number of subjects: 61651
Study 37602458 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping group (high-risk subgroup received candesartan 8 mg/day for 6 weeks; low-risk subgroup received perindopril 4 mg/day)
Number of subjects: 68
Study 37602458 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping group
Number of subjects: 68
Study 37602458 — intervention group
Group type: COMPARATOR
Intervention: Control group (not genotyped, received perindopril 4 mg/day)
Number of subjects: 68
Study 37602458 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 37602458 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk subgroup
Number of subjects: 68
Study 37602458 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 68
Study 37602534 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-ICS/LABA
Number of subjects: 38276
Study 37602534 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-ICS/LABA
Number of subjects: 38276
Study 37602534 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-ICS/LAMA
Number of subjects: 38276
Study 37602534 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-ICS
Number of subjects: 38276
Study 37602534 — intervention group
Group type: COMPARATOR
Intervention: MD-ICS
Number of subjects: 38276
Study 37602534 — intervention group
Group type: COMPARATOR
Intervention: ICS/LABA
Number of subjects: 38276
Study 37602537 — intervention group
Group type: EXPERIMENTAL
Intervention: GET2HOME transition bundle intervention
Number of subjects: 0
Study 37602537 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital-based care coordination discharge process
Number of subjects: 0
Study 37602906 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 0
Study 37602906 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37603048 — intervention group
Group type: EXPERIMENTAL
Intervention: Zosuquidar (Zos) plus gemtuzumab ozogamicin (GO)
Number of subjects: 41
Study 37603090 — intervention group
Group type: EXPERIMENTAL
Intervention: E/MILOS repair
Number of subjects: 615
Study 37603097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 37603097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37603106 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive score for pneumothorax occurrence
Number of subjects: 498
Study 37603106 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 498
Study 37603205 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% QD
Number of subjects: 245
Study 37603205 — intervention group
Group type: COMPARATOR
Intervention: Ripasudil 0.4% BID
Number of subjects: 245
Study 37603325 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to an EVT-capable stroke center (n=137)
Number of subjects: 302
Study 37603325 — intervention group
Group type: COMPARATOR
Intervention: Transfer to the nearest local stroke center (n=165)
Number of subjects: 302
Study 37603325 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to an EVT-capable stroke center
Number of subjects: 302
Study 37603328 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide, 14 mg daily
Number of subjects: 89
Study 37603328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 37603505 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypoxemia group (OI ≤ 200 mm Hg)
Number of subjects: 88
Study 37603505 — intervention group
Group type: EXPERIMENTAL
Intervention: ANG II concentration
Number of subjects: 88
Study 37603505 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 88
Study 37603505 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI
Number of subjects: 88
Study 37603600 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2627
Study 37603600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2627
Study 37603816 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and pemetrexed
Number of subjects: 40
Study 37603835 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with pan-enteric capsule endoscopy (PCE)
Number of subjects: 46
Study 37603835 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mucosal healing (MH) at 52 weeks
Number of subjects: 46
Study 37603846 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease (IBD) patients
Number of subjects: 3898
Study 37604132 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath analysis using gas chromatography-mass spectrometry (GC/MS)
Number of subjects: 142
Study 37604132 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 142
Study 37604132 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with asthma or wheeze
Number of subjects: 142
Study 37604516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Dexmedetomidine A
Number of subjects: 52
Study 37604516 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and Saline 0.9% B
Number of subjects: 52
Study 37604629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir and lamivudine (DTG/3TC)
Number of subjects: 70
Study 37604629 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir, abacavir, and lamivudine (DTG/ABC/3TC)
Number of subjects: 70
Study 37604637 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prophylactic antibiotics administered within 24 hours
Number of subjects: 20000
Study 37604637 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of prophylactic antibiotics administered within 24 hours
Number of subjects: 20000
Study 37604637 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prophylactic antibiotics
Number of subjects: 20000
Study 37604637 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of prophylactic antibiotics
Number of subjects: 20000
Study 37604649 — intervention group
Group type: COMPARATOR
Intervention: Rural population
Number of subjects: 8452
Study 37604662 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide + 4 mg dexamethasone
Number of subjects: 209
Study 37604662 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide + 16 mg dexamethasone
Number of subjects: 209
Study 37604662 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dexamethasone (4 mg)
Number of subjects: 209
Study 37604662 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (16 mg)
Number of subjects: 209
Study 37604693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs)
Number of subjects: 100
Study 37604693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 37604857 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 532
Study 37604981 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib plus intensive chemotherapy (cytarabine and daunorubicin)
Number of subjects: 729
Study 37604981 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib plus non-intensive chemotherapy (azacitidine)
Number of subjects: 729
Study 37604981 — intervention group
Group type: COMPARATOR
Intervention: Glasdegib
Number of subjects: 729
Study 37604988 — intervention group
Group type: EXPERIMENTAL
Intervention: FUS-MB treatment delivered before 1st and 5th fractions of RT (within 1 hour)
Number of subjects: 8
Study 37604988 — intervention group
Group type: COMPARATOR
Intervention: Fractionated RT (5 or 10 fractions)
Number of subjects: 8
Study 37605035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 0
Study 37605035 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37605068 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-Ag
Number of subjects: 229
Study 37605068 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-N
Number of subjects: 229
Study 37605068 — intervention group
Group type: COMPARATOR
Intervention: ADAMTS13 activity
Number of subjects: 229
Study 37605068 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF cleavage
Number of subjects: 229
Study 37605068 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF activity
Number of subjects: 229
Study 37605068 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-Ag levels and VWF-N
Number of subjects: 229
Study 37605068 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMTS13-Act
Number of subjects: 229
Study 37605150 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART with 100% adherence
Number of subjects: 0
Study 37605150 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART with side effects
Number of subjects: 0
Study 37605150 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART with opportunistic infections
Number of subjects: 0
Study 37605150 — intervention group
Group type: EXPERIMENTAL
Intervention: High HIV viral load
Number of subjects: 0
Study 37605150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD4 count
Number of subjects: 0
Study 37605150 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of comorbidities
Number of subjects: 0
Study 37605151 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch Client Satisfaction with Device (D-CSD)
Number of subjects: 76
Study 37605193 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant scaling and root-planing (Q-SRP)
Number of subjects: 46
Study 37605193 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth disinfection (FMD)
Number of subjects: 46
Study 37605227 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSC-CM combined with 5% minoxidil
Number of subjects: 0
Study 37605227 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% as placebo combined with 5% minoxidil
Number of subjects: 0
Study 37605251 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical ablation using multiple RF applicators
Number of subjects: 55
Study 37605274 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 0
Study 37605542 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular consumption of grapes
Number of subjects: 0
Study 37605542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37605636 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1654
Study 37605636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1654
Study 37606172 — intervention group
Group type: COMPARATOR
Intervention: MHFA training
Number of subjects: 22604
Study 37606364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipid nanocrystal (LNC) amphotericin B + flucytosine (1.8 g/d for 2 weeks, then 1.2 g/d for 6 weeks)
Number of subjects: 121
Study 37606364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipid nanocrystal (LNC) amphotericin B with IV loading doses + flucytosine
Number of subjects: 121
Study 37606364 — intervention group
Group type: COMPARATOR
Intervention: IV amphotericin + flucytosine
Number of subjects: 121
Study 37606364 — intervention group
Group type: COMPARATOR
Intervention: Comparison of adverse events between LNC amphotericin and IV amphotericin
Number of subjects: 121
Study 37606495 — intervention group
Group type: EXPERIMENTAL
Intervention: luspatercept (BMS-986346/ACE-536)
Number of subjects: 1
Study 37606495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 37606572 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm covered TIPS
Number of subjects: 100
Study 37606572 — intervention group
Group type: COMPARATOR
Intervention: EVL plus propranolol
Number of subjects: 100
Study 37606606 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD daily in cycle 1
Number of subjects: 12
Study 37606606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 37606641 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (starting dose 72 mg/m2/day) with vincristine (1.5 mg/m2 on days 1 and 8) and irinotecan (50 mg/m2 on days 1-5)
Number of subjects: 21
Study 37606641 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (MTD/RP2D of 82 mg/m2 in sequential schedule)
Number of subjects: 21
Study 37606641 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib combined with vincristine and irinotecan
Number of subjects: 21
Study 37606672 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-IC bypass surgery plus medical therapy (surgical group; n=161)
Number of subjects: 324
Study 37606672 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (medical group; n=163)
Number of subjects: 324
Study 37606852 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 367
Study 37606856 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropic infections (viral, bacterial, protozoal) assessed through serology testing in patients treated with immune checkpoint inhibitors (ICI).
Number of subjects: 61